JP2024538140A5 - - Google Patents
Info
- Publication number
- JP2024538140A5 JP2024538140A5 JP2024522608A JP2024522608A JP2024538140A5 JP 2024538140 A5 JP2024538140 A5 JP 2024538140A5 JP 2024522608 A JP2024522608 A JP 2024522608A JP 2024522608 A JP2024522608 A JP 2024522608A JP 2024538140 A5 JP2024538140 A5 JP 2024538140A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- concentration
- pharmaceutical formulation
- buffer
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021124200 | 2021-10-15 | ||
| CNPCT/CN2021/124200 | 2021-10-15 | ||
| CNPCT/CN2022/118065 | 2022-09-09 | ||
| CN2022118065 | 2022-09-09 | ||
| PCT/CN2022/125017 WO2023061424A1 (en) | 2021-10-15 | 2022-10-13 | Pharmaceutical formulation comprising anti-ox40 monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538140A JP2024538140A (ja) | 2024-10-18 |
| JP2024538140A5 true JP2024538140A5 (https=) | 2025-10-21 |
Family
ID=85987310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522608A Pending JP2024538140A (ja) | 2021-10-15 | 2022-10-13 | 抗ｏｘ４０モノクローナル抗体を含む医薬製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250282882A1 (https=) |
| EP (1) | EP4415754A4 (https=) |
| JP (1) | JP2024538140A (https=) |
| KR (1) | KR20240109250A (https=) |
| CN (1) | CN118541166A (https=) |
| AU (1) | AU2022367611A1 (https=) |
| CA (1) | CA3235879A1 (https=) |
| CL (1) | CL2024001157A1 (https=) |
| IL (1) | IL312138A (https=) |
| MX (1) | MX2024004619A (https=) |
| PE (1) | PE20241351A1 (https=) |
| TW (1) | TW202323280A (https=) |
| WO (1) | WO2023061424A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20230255A1 (es) * | 2020-04-17 | 2023-02-07 | Hutchison Medipharma Ltd | Anticuerpo anti-ox40 y usos del mismo |
| TW202600166A (zh) * | 2024-03-04 | 2026-01-01 | 新加坡商創響私人有限公司 | 包含ｏｘ４０靶向抗體的藥物組合物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100014588A (ko) * | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
| SG11201607969XA (en) * | 2014-03-31 | 2016-10-28 | Genentech Inc | Anti-ox40 antibodies and methods of use |
| WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
| WO2020016417A1 (en) * | 2018-07-19 | 2020-01-23 | Ichnos Sciences S.A. | Liquid antibody formulation |
| WO2020063668A1 (zh) * | 2018-09-25 | 2020-04-02 | 信达生物制药(苏州)有限公司 | 包含抗ox40抗体的制剂、其制备方法及其用途 |
| US20220273796A1 (en) * | 2019-07-19 | 2022-09-01 | Ichnos Sciences SA | Lyophilized antibody formulation |
| WO2021190582A1 (zh) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 一种抗ox40抗体药物组合物及其用途 |
-
2022
- 2022-10-11 TW TW111138442A patent/TW202323280A/zh unknown
- 2022-10-13 EP EP22880360.7A patent/EP4415754A4/en active Pending
- 2022-10-13 MX MX2024004619A patent/MX2024004619A/es unknown
- 2022-10-13 PE PE2024000811A patent/PE20241351A1/es unknown
- 2022-10-13 IL IL312138A patent/IL312138A/en unknown
- 2022-10-13 JP JP2024522608A patent/JP2024538140A/ja active Pending
- 2022-10-13 US US18/701,246 patent/US20250282882A1/en active Pending
- 2022-10-13 KR KR1020247016091A patent/KR20240109250A/ko active Pending
- 2022-10-13 WO PCT/CN2022/125017 patent/WO2023061424A1/en not_active Ceased
- 2022-10-13 AU AU2022367611A patent/AU2022367611A1/en active Pending
- 2022-10-13 CA CA3235879A patent/CA3235879A1/en active Pending
- 2022-10-13 CN CN202280069427.XA patent/CN118541166A/zh active Pending
-
2024
- 2024-04-12 CL CL2024001157A patent/CL2024001157A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220175663A1 (en) | Stable liquid antibody formulation | |
| TWI728953B (zh) | 治療或預防偏頭痛之方法 | |
| KR102553870B1 (ko) | 인간 카나비노이드 1(cb1) 수용체 결합 항체 | |
| AU2019262953B2 (en) | Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof | |
| TW201100100A (en) | Pharmaceutical formulation containing improved antibody molecules | |
| AU2013255457A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| JP2022532927A5 (https=) | ||
| JP2025501028A5 (https=) | ||
| TW202220702A (zh) | 一種含抗體藥物偶聯物的醫藥組成物及其用途 | |
| WO2023006055A1 (en) | Anti-pd-1 antibody pharmaceutical composition and use thereof | |
| US20130122013A1 (en) | Anti-ferroportin 1 monoclonal antibodies and uses thereof | |
| JP2024538140A5 (https=) | ||
| JP2024510142A5 (https=) | ||
| JP2025503614A5 (https=) | ||
| JP2025503339A5 (https=) | ||
| JP2024515968A5 (https=) | ||
| JP2023502398A5 (https=) | ||
| JP2022519796A5 (https=) | ||
| TW202334207A (zh) | 一種包含抗ｃｄ７９ｂ抗體藥物偶聯物的醫藥組成物及其用途 | |
| CN116391041A (zh) | 一种含抗结缔组织生长因子抗体的药物组合物 | |
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| RU2024127270A (ru) | Препараты, содержащие биспецифическое антитело против claudin18.2/cd3, способ их получения и применение | |
| CA3097711C (en) | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof | |
| RU2024133531A (ru) | Стабильные высококонцентрированные составы на основе аргинина, содержащие антитело к pd-1, и способы их применения | |
| RU2024133528A (ru) | Стабильные высококонцентрированные составы на основе хлорида натрия, содержащие антитело к pd-1, и способы их применения |